Clinical Trial · NCT03803475

Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients

Overview

The investigators are imaging patients with prostate cancer using a new Positron Emission Tomography (PET) imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detect prostate cancer.

Sponsor

University of California, San Francisco

Phase

Phase 3

Contacts

Thomas Hope, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03803475

Drug / Compound

PSMA-11

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC
Linker: Ahx

Eligibility

Inclusion

  • Histopathologically proven prostate adenocarcinoma.
  • Initial staging with intermediate to high risk prostate cancer.
  • Biochemical recurrence after initial therapy.
  • Concern for metastatic disease in one of the following settings:

Exclusion

  • 1\. Patient unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.